摘要
目的评价HIFU联合奥曲肽治疗晚期胰腺癌的近期疗效与不良反应的观察。方法病理确诊的晚期胰腺癌患者46例(有可测量病灶者),随机分为热疗组和联合组,联合组采用FBY01北大研制的高强度聚焦超声联合奥曲肽治疗,两组均至少治疗2周期后评价疗效。结果全组均可评价疗效。联合组临床受益反应率为75.0%(18/24),热疗组为36.4%(8/22),2组比较有非常显著差异(P<0.01)。联合组治疗前后及两对照组治疗后比较,都有非常显著差异(P<0.01)。热疗组中位生存期约8.8月,联合组中位生存期达到10.8个月,P>0.05。两组的近期有效率,中位生存时间无显著差异(P>0.05)。毒副作用轻微,二者无显著性差异。结论HIFU联合奥曲肽治疗晚期胰腺癌临床受益反应率改善明显,VEGF水平下降明显,且毒副反应轻,病人能耐受,值得临床推广应用。
Objective To evaluate the recent curative efficacy and security of High intensity focused ultrasound (HIFU) in combination with Octreotide in patients with advanced pancreatic carcinoma. Method 46 patients with advanced pancreatic carcinoma by pathologic diagnosis were divided into Group HIFU and Group Combination [treated by HIFU(FEP-BY01) in combination with Octreotide] at random. All patients must be treated for two cycles at least. Results All cases could be evaluated. CBR(Clinical Beneficial Rate) in Group Combination was 75.0%(18/24), while in the HIFU it was 36.4%(8/22). There was significant difference(P<0.01) between them. The level of VEGF has also significant difference(P<0.01) between pretherapy and posttherapy in Group Combination, and posttherapy between the two groups as well. Median survival time was 8.8 months in Group HIFU, and 10.8 months in Group Combination. No significant difference between the two groups in the recent curative efficacy and median survival time. All patients had mild treatment-related adverse events. No significant difference between the two groups was found. Conclusion This study shows that HIFU in combination with Octreotide was a new, efficacious, secure, for the patients with advanced pancreatic carcinoma. The decrease of VEGF level was also observed in this regime.
出处
《实用临床医药杂志》
CAS
2005年第5期28-31,共4页
Journal of Clinical Medicine in Practice
基金
江苏省卫生厅科研指导性课题(Z200504)
关键词
HIFU
奥曲肽
晚期胰腺癌
HIFU
Octreotide
Advanced pancreatic carcinoma
